mohd izzuan
- GoodRx (NASDAQ:GDRX) is down ~21% in Thursday trading after announcing a Q3 revenue guidance range that did not include the consensus and saying that prior full-year guidance will be in the low-end of the range.
- The company sees Q3 revenue of $193M-$197M (midpoint $195M), below the consensus estimate of $202.45M.
- For 2024, revenue is expected at the low end of its previous outlook of $800M-$810M (midpoint $805M). Consensus is $806.39M.
- In Q2, financial results were in-line on the top and a miss on the bottom line.
- On an adjusted basis, net income rose ~17% year over year to ~$32.4M ($.08 diluted EPS vs. $.07).
- As of the end of the quarter (June 30), GoodRx recorded 6.6M active monthly customers compared to 6.1M in the year-ago period. However, subscription plans declined to 696K from 969K.
Source link
